Phase 1 Non-Hodgkin's Lymphoma Clinical Trials
18 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–18 of 18 trials
Recruiting
Phase 1Phase 2
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
Phase 1
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Non-Hodgkin's Lymphoma+1 more
City of Hope Medical Center15 enrolled1 locationNCT05801913
Recruiting
Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
LymphomaNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Baylor College of Medicine136 enrolled3 locationsNCT01555892
Recruiting
Phase 1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
AbbVie165 enrolled14 locationsNCT06667687
Recruiting
Phase 1
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Baylor College of Medicine52 enrolled2 locationsNCT04664179
Recruiting
Phase 1
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
PeproMene Bio, Inc.36 enrolled6 locationsNCT05370430
Recruiting
Phase 1Phase 2
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
Ottawa Hospital Research Institute60 enrolled3 locationsNCT03765177
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin LymphomaNon-Hodgkin's LymphomaLymphomas Non-Hodgkin's B-Cell+2 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Institute of Hematology and Blood Transfusion, Czech Republic10 enrolled1 locationNCT05054257
Recruiting
Phase 1Phase 2
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Non-Hodgkin's Lymphoma
Beijing Mabworks Biotech Co., Ltd.132 enrolled1 locationNCT05806099
Recruiting
Phase 1
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Advanced Solid TumorNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Tarapeutics Science Inc.26 enrolled1 locationNCT05650580
Recruiting
Phase 1Phase 2
Chidamide Bridging for CAR-T Therapy
Non-Hodgkin's Lymphoma
Chinese PLA General Hospital120 enrolled13 locationsNCT05370547
Recruiting
Phase 1Phase 2
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
B-cell Non-Hodgkin's Lymphoma
Shanghai Hengrui Pharmaceutical Co., Ltd.132 enrolled1 locationNCT06104553
Recruiting
Phase 1Phase 2
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd100 enrolled2 locationsNCT05768529
Recruiting
Phase 1
CAR T cell therapy for CD19-positive cancer - phase I clinical trial
B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.
Metro North Hospital and Health Service31 enrolled1 locationACTRN12621000762853
Recruiting
Phase 1Phase 2
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Chinese PLA General Hospital30 enrolled1 locationNCT02259556
Not Yet Recruiting
Phase 1
A trial examining the bioavailability of 4 doses of 3 different formulations of Afuresertib - a Gelatin Formulation and Two Prototype Formulations of Afuresertib, in Normal Healthy Volunteers in both the fasted and non-fasted states .
Oncology (general Cancer). Previous research with this agent has been conducted in Multiple Myeloma. Hodgkins Disease, non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Langerhans Cell Histiocytosis
GlaxoSmithKline36 enrolled1 locationACTRN12613000409774